10-Q: Anteris Q3 Loss Widens Amid R&D Surge, Secures $25.2M Capital

Anteris Technologies Global Corp. reported increased losses in Q3 2025 as R&D expenses surged for its DurAVR THV System, while successfully raising $25.2 million post-period to fund ongoing operations and clinical trials.

Summary

• Net loss after income tax for the nine months ended September 30, 2025, increased by 15% to $65.2 million from $56.8 million in the prior year period.
• Research and development (R&D) expenses rose by 30% to $49.6 million for the nine months ended September 30, 2025, driven by manufacturing upscaling and preparatory activities for the PARADIGM Trial.
• Net sales for the nine months ended September 30, 2025, decreased by 26% to $1.6 million, primarily due to the expiration of a distribution agreement with LeMaitre in January 2025.
• Cash, cash equivalents, and restricted cash significantly declined to $9.1 million as of September 30, 2025, from $70.5 million at December 31, 2024.
• The company completed a private placement in October/November 2025, raising approximately $25.2 million in gross proceeds.
• Regulatory approvals were secured from the Danish Medicines Agency (October 2025) and the U.S. FDA (early November 2025) to initiate the global pivotal PARADIGM Trial for the DurAVR THV System, with first patients enrolled and treated in October 2025.
• Material weaknesses in internal control over financial reporting, related to procedures, controls, and segregation of duties, remained unremediated as of September 30, 2025.

Sentiment

Score: 4

Explanation: While the company achieved significant regulatory milestones and a capital raise post-period, the substantial increase in net loss, high cash burn, and explicit 'going concern' warning indicate significant financial challenges and reliance on future funding. The unremediated material weaknesses in internal controls also add a layer of concern. The positive clinical progress is overshadowed by the immediate financial pressures.

Positives

• Successfully completed a private placement in October/November 2025, raising $25.2 million in gross proceeds, providing crucial funding for ongoing operations.
• Secured the first European regulatory clearance from the Danish Medicines Agency in October 2025, marking a significant step towards commercialization.
• Received U.S. FDA approval in early November 2025 to initiate the global pivotal PARADIGM Trial for the DurAVR THV System.
• Enrolled and treated the first patients in the PARADIGM Trial in October 2025, formally initiating the clinical study.
• Strengthening operational infrastructure, including quality management system (QMS) buildout and manufacturing scale-up, to support upcoming clinical activities and future demand.
• Mitigating supply chain risks by sourcing ADAPT tissue for the DurAVR THV from both the United States and Australia.

Negatives

• Net loss after income tax increased by 15% to $65.2 million for the nine months ended September 30, 2025, compared to $56.8 million in the prior year period.
• Cash, cash equivalents, and restricted cash decreased significantly by over 87% to $9.1 million as of September 30, 2025, from $70.5 million at December 31, 2024.
• Net cash used in operating activities increased by 38% to $59.3 million for the nine months ended September 30, 2025, indicating a higher operational cash burn rate.
• Net sales decreased by 26% to $1.6 million for the nine months ended September 30, 2025, primarily due to the expiration of a key distribution agreement.
• The company explicitly states that its current cash on hand, even with the proceeds from the recent private placement, is not expected to fund its cash needs for the next 12 months, indicating persistent capital requirements.
• Material weaknesses in internal control over financial reporting, identified in prior periods, remained unremediated as of September 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for one year from the issuance date of the financial statements due to recurring operating losses and cash outflows.
• There is no assurance that the global pivotal PARADIGM Trial will be successful or that Premarket Approval (PMA) from the FDA will be obtained as a result.
• The current FDA approval to proceed with the PARADIGM Trial could be revoked, or the study could be unsuccessful.
• Even if PMA is obtained for the DurAVR THV System, the FDA or other regulatory authorities may require expensive or burdensome post-market testing or controls.
• Any delay in, or failure to receive or maintain, regulatory clearance or approval for the DurAVR THV System could prevent the company from generating revenue or achieving profitability.
• Future capital requirements are difficult to forecast and will depend on factors such as the scope, results, and timing of clinical trials, costs of obtaining PMA, and costs of establishing marketing, sales, and distribution capabilities.
• Raising additional capital through equity offerings may result in dilution to existing stockholders.
• If additional capital is raised through debt financing, the company may be subject to covenants limiting or restricting its ability to take specific actions.

Future Outlook

The company anticipates continued losses for the foreseeable future and does not expect to generate significant revenue until after obtaining regulatory approvals and commencing sales of the DurAVR THV System. It will require additional capital to fund operations, including completing R&D and commercialization. The PARADIGM Trial is designed to provide primary clinical evidence for FDA Premarket Approval (PMA) in the U.S. and parallel CE Mark approval in Europe. Manufacturing capacity is being scaled up, and supply chain risks are being mitigated for the PARADIGM Trial and future commercial demand.

Management Comments

• "We anticipate that we will continue to incur losses for the foreseeable future and there can be no assurance that we will ever achieve or maintain profitability."
• "We expect expenses for our research, clinical validation, development, design, manufacturing and marketing will increase and, as a result, we will need additional capital to fund our operations."
• "Any future funding could involve a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements, strategic alliances and licensing arrangements."
• "We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all."
• "Any failure to raise capital or enter into such other arrangements as and when needed could have a negative impact on our financial condition and our ability to market our products."
• "The audit report covering the December 31, 2024 and 2023 consolidated financial statements contains a paragraph that states that our recurring losses from operations raise substantial doubt about our ability to continue as a going concern."
• "Our management has determined that the activities of the business as reviewed by our Company’s Vice Chairman and CEO, who also serves as the Company’s chief operating decision maker, are one segment, being the development and commercialization of the ADAPT anti-calcification tissue. This is focused on the DurAVR THV System."

Industry Context

Anteris operates in the structural heart medical technology industry, focusing on transcatheter heart valves for aortic stenosis. This is a highly competitive and capital-intensive sector, characterized by extensive R&D, rigorous clinical trials, and lengthy regulatory approval processes (FDA PMA, CE Mark). The company's strategy to develop a 'biomimetic valve' with proprietary ADAPT tissue aims to differentiate it in a market with established players. The need for significant capital infusion and the inherent uncertainties of clinical trials and regulatory pathways are typical for companies in this development stage of the medtech industry.

Management Changes

Corporate Governance

Legal Proceedings

• Not party to any material legal proceedings, and no such proceedings are threatened against the company.

Related Party Transactions

• The company consolidates v2vmedtech, inc. (v2v) as a Variable Interest Entity (VIE), having contributed $1.0 million during the three months and $1.7 million during the nine months ended September 30, 2025, to finance its operations.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and potential volatility due to ongoing losses and 'going concern' uncertainty. Positive news on clinical trials and regulatory approvals could provide upside.
• Employees may see job stability and growth opportunities in R&D and manufacturing due to increased investment and headcount expansion, but the overall financial health poses long-term risk.
• Potential future customers for the DurAVR THV System benefit from progress in clinical trials and regulatory approvals, indicating eventual product availability to address aortic stenosis.
• Creditors face elevated risk due to the 'going concern' warning and the company's reliance on continuous capital raises to fund operations.
• Regulatory authorities are actively engaged with the company, which is progressing through the necessary approval pathways for its medical devices.

Next Steps

• Continue the global pivotal PARADIGM Trial for the DurAVR THV System.
• Generate clinical evidence required to support a Premarket Approval (PMA) application in the United States.
• Progress towards CE Mark approval in Europe in parallel with PMA.
• Expand manufacturing and distribution capabilities.
• Comply with ongoing post-market regulatory requirements.
• Address and remediate material weaknesses in internal control over financial reporting.
• Seek additional capital infusion through issuance of shares, debt instruments, or other securities.

Key Dates

Recommendation

The company is in a critical development stage with significant R&D expenses and recurring losses, leading to an explicit 'going concern' warning. While the recent capital raise and regulatory approvals for the PARADIGM Trial are positive milestones, they are expected and necessary for continued operations. The stock is highly speculative, driven by future clinical success and commercialization. A 'hold' recommendation reflects the high risk but also the potential for substantial upside if the DurAVR THV System proves successful in trials and gains market approval, balancing the current financial challenges with future growth prospects. Investors should monitor trial results and further funding activities closely.

Keywords

Anteris Technologies Global Corp, DurAVR THV System, Transcatheter Heart Valve, Aortic Stenosis, ADAPT tissue technology, PARADIGM Trial, FDA approval, CE Mark, Medical Devices, Cardiovascular, Clinical Trials, Biomimetic Valve, Capital Raise, SEC 10-Q, Financial Results